


Applicants: Jeremy Green et al.
Application No.: 10/808,678

THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1-46. (Canceled)

47. (Previously presented) A pharmaceutical composition comprising a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein:

R¹ is Ar¹;

R² is hydrogen;

T is CH;

A¹ is C-halogen, C-CN, or C-R;

each of A² and A³ is, independently, CR⁴;


R⁴ is selected from halogen, NO₂, CN, -(L)_mR, -(L)_mAr¹, or -(L)_mCy¹; or

two R⁴ groups on adjacent atoms are taken together to form an optionally substituted 5-7 membered partially unsaturated or fully unsaturated ring having 0-3 heteroatoms independently selected from oxygen, sulfur, or nitrogen, wherein[[:]] each ring formed by two R⁴ groups on adjacent atoms taken together is optionally substituted with up to 4 occurrences of Z-R^X;

Applicants: Jeremy Green et al.
Application No.: 10/808,678

L is a C₁₋₆ alkylidene chain wherein one methylene unit of L is optionally replaced by -O-, -N(R)-, -N(R)C(O)-, -C(O)-, -C(O)N(R)-, -SO₂N(R)-, or -N(R)SO₂-; m is 0 or 1;

Ar¹ is



Ar¹ and Cy¹ are each optionally substituted with up to 5 occurrences of Z-R^X; wherein each occurrence of Z is independently a bond or a C₁₋₆ alkylidene chain, wherein up to two non-adjacent methylene units of Z are optionally replaced by -S-, -O-, -N(R)-,

-N(R)C(O)-, -C(O)N(R)-, -SO₂N(R)-, or -N(R)SO₂-;

each occurrence of R^X is independently selected from -R', halogen, NO₂, CN, -OR',

-SR', or -N(R')₂,

each occurrence of R is independently hydrogen or a C₁₋₆ aliphatic group; and

each occurrence of R' is independently hydrogen, a C₁₋₆ aliphatic group, a C₆₋₁₀ aryl ring,

a heteroaryl ring having 5-10 ring atoms, or a heterocycl ring having 3-10 ring


atoms; or

Applicants: Jeremy Green et al.
Application No.: 10/808,678

R and R' or two occurrences of either R or R' are taken together with the atoms to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
two occurrences of either R' or R on the same nitrogen are taken together with the nitrogen atom to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

48-49. (Canceled)

50. (Currently amended) A method of inhibiting c-MET kinase activity in a biological sample, wherein said biological sample is selected from a cell culture, biopsied material obtained from a mammal, saliva, urine, feces, semen, or tears, or an extract thereof; which method comprises contacting said biological sample with a composition according to claim 47 or a compound of formula I:



¶

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is Ar¹;

R² is hydrogen;

T is CH;

A¹ is C-halogen, C-CN, or C-R;

each of A² and A³ is, independently, CR⁴;


Applicants: Jeremy Green et al.
Application No.: 10/808,678

R^4 is selected from halogen, NO_2 , CN , $(\text{L})_m\text{R}$, $(\text{L})_m\text{Ar}^+$, or $(\text{L})_m\text{C}y^+$; or
two R^4 groups on adjacent atoms are taken together to form an optionally substituted 5-7
membered partially unsaturated or fully unsaturated ring having 0-3 heteroatoms
independently selected from oxygen, sulfur, or nitrogen, wherein each ring formed by
two R^4 groups on adjacent atoms taken together is optionally substituted with up to 4
occurrences of $Z\text{-}R^X$;


L is a C_{1-6} alkylidene chain wherein one methylene unit of L is optionally replaced by
 $-O-$, $N(\text{R})-$, $N(\text{R})\text{C}(\text{O})-$, $\text{C}(\text{O})-$, $\text{C}(\text{O})\text{N}(\text{R})-$, $\text{SO}_2\text{N}(\text{R})-$, or $\text{N}(\text{R})\text{SO}_2-$;

m is 0 or 1;


Ar^+ is selected from



Applicants: Jeremy Green et al.
Application No.: 10/808,678



C_Y^+ is selected from



wherein;

Ar^+ and C_Y^+ are each optionally substituted with up to 5 occurrences of $\text{Z}-\text{R}^X$; wherein each occurrence of Z is independently a bond or a C_{+6} -alkylidene chain, wherein up to two non-adjacent methylene units of Z are optionally replaced by S , O , $\text{N}(\text{R})$, $-\text{N}(\text{R})\text{C}(\text{O})$, $-\text{C}(\text{O})\text{N}(\text{R})$, $-\text{SO}_2\text{N}(\text{R})$, or $-\text{N}(\text{R})\text{SO}_2-$;

each occurrence of R^X is independently selected from R' , halogen, NO_2 , CN , OR' , $-\text{SR}'$, or $-\text{N}(\text{R}')_2$;

each occurrence of R is independently hydrogen or a C_{1-6} -aliphatic group; and

each occurrence of R' is independently hydrogen, a C_{1-6} -aliphatic group, a C_{6-10} -aryl ring, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms; or

Applicants: Jeremy Green et al.
Application No.: 10/808,678

~~R and R' or two occurrences of either R or R' are taken together with the atoms to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or~~

~~two occurrences of either R' or R on the same nitrogen are taken together with the nitrogen atom to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

51-80. (Canceled)

81. (Previously presented) The composition according to claim 47, wherein A² is CR⁴ and R⁴ is halogen, CN, -(L)_mR, -(L)_mAr¹, or -(L)_mCy¹.


82. (Canceled)

83. (Previously presented) The composition according to claim 81, wherein A² is CR⁴ and R⁴ is halogen or R.

84. (Previously presented) The composition according to claim 81, wherein A² is CR⁴ and R⁴ is -(L)_mR, wherein L is -O- or -N(R)-.


85. (Previously presented) The composition according to claim 81, wherein A² is CR⁴, R⁴ is -(L)_mCy¹, m is 0 and Cy¹ is

Applicants: Jeremy Green et al.
Application No.: 10/808,678




86. (Cancelled)

87. (Previously presented) The composition according to claim 81, wherein A² is CR⁴, R⁴ is -(L)_mR, and compounds have the formula **IE-1**:



IE-1.


88. (Previously presented) The composition according to claim 81, wherein A² is CR⁴, R⁴ is -(L)_mAr¹, and compounds have the formula **IE-2**:



IE-2 .

Applicants: Jeremy Green et al.
Application No.: 10/808,678

89. (Previously presented) The composition according to claim 81, wherein A² is CR⁴, R⁴ is -(L)_mCy¹, and compounds have the formula IE-3:



IE-3.




90. (Previously presented) The composition according to claim 47, wherein A³ is CR⁴ and R⁴ is halogen, CN, -(L)_mR, -(L)_mAr¹, or -(L)_mCy¹.

91. (Canceled)


92. (Previously presented) The composition according to claim 90, wherein A³ is CR⁴ and R⁴ is halogen or R.

93. (Previously presented) The composition according to claim 90, wherein A³ is CR⁴ and R⁴ is -(L)_mR, wherein L is -O- or -N(R)-.

94. (Previously presented) The composition according to claim 90, A³ is CR⁴, R⁴ is -(L)_mCy¹, m is 0 and Cy¹ is




or




Applicants: Jeremy Green et al.
Application No.: 10/808,678

95. (Canceled)

96. (Previously presented) The composition according to claim 90, wherein A³ is CR⁴, R⁴ is -(L)_mR, and compounds have the formula **IF-1**:




97. (Previously presented) The composition according to claim 90, wherein A³ is CR⁴, R⁴ is -(L)_mAr¹, and compounds have the formula **IF-2**:



98. (Previously presented) The composition according to claim 90, wherein A³ is CR⁴, R⁴ is -(L)_mCy¹, and compounds have the formula **IF-3**:


Applicants: Jeremy Green et al.
Application No.: 10/808,678




IF-3 .

99-100. (Canceled)


101. (Currently amended) The composition according to claim 47, selected from one of the following compounds:




I-1,




I-2,




I-3,



I-4,




I-11,




I-12,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-13,




I-14,




I-15,




I-17,




I-18,




I-19,




I-20,




I-21,



I-22,




I-23,




I-24,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-25,




I-26,




I-27,




I-28,



I-29,




I-31,




I-32,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-33,




I-34,



I-35,



I-36,



or I-37 .